Wholesale · Research use only
Wholesale Retatrutide (LY3437943)
An investigational triple receptor agonist peptide (GLP-1 / GIP / glucagon) developed by Eli Lilly. We supply it wholesale in lyophilised powder and predosed pen formats to CROs, pharmaceutical R&D groups, universities, clinics and qualified B2B distributors — strictly for research use only, not for human consumption or clinical use.
≥98% HPLC & MSPowder & predosed pensMOQ from 1g
GMP · ISO · HACCPUK & Berlin manufacturingThird-party testedManufacturer direct since 2018
Overview
A triple GLP-1 / GIP / glucagon agonist
Retatrutide (LY3437943) is an investigational triple receptor agonist peptide developed by Eli Lilly, simultaneously targeting the GLP-1, GIP and glucagon receptors. This tri-agonist mechanism distinguishes it from both single GLP-1 agonists such as semaglutide and dual agonists such as tirzepatide, with Phase II data reporting among the highest weight reduction figures seen in any GLP-1 class agent to date. It is currently in Phase II/III clinical development for obesity and metabolic disease.SARMs Direct supplies wholesale Retatrutide in lyophilised powder and predosed pen formats to CROs, pharmaceutical R&D groups, universities, clinics and qualified B2B distributors. All supply is strictly for research use only and is not available for human consumption or clinical use.
Compound specifications
Retatrutide at a glance
| Compound name | Retatrutide |
| Development code | LY3437943 |
| Compound class | Triple Receptor Agonist Peptide (GLP-1 / GIP / Glucagon) |
| CAS number | 2270038-40-3 |
| Developer | Eli Lilly and Company |
| Administration | Subcutaneous injection (weekly) |
| Development status | Phase II / III (obesity & metabolic disease) |
| Purity | ≥98% (HPLC & MS verified) |
| Supply form | Lyophilised powder in sterile vials; predosed pens |
| Storage | –20°C recommended for long-term storage. Temperature-controlled shipping available. |
Available formats & MOQs
Two supply formats
FORMAT 01
Lyophilised powder
MOQ 1g, bulk supply from 10g, custom batch sizes on request. Supplied in sterile, sealed vials, vacuum-sealed and shipped with temperature control where required. Full COA, HPLC and MS data included per batch.FORMAT 02
Predosed research pens
Prefilled with sterile Retatrutide solution, with a dial-a-dose mechanism for precision and repeatability. No vials, syringes or manual reconstitution required. Contact us for dose concentrations, unit quantities and MOQ.FORMAT 03
Custom batch sizes
Available for both formats on request. Contact us with your target quantity, delivery location and documentation requirements.Research context
How the tri-agonist mechanism works
All data cited refers to publicly available clinical trial readouts. All products are supplied for research purposes only and are not intended for human or veterinary use. No claims of safety or efficacy are made.
For oral GLP-1 pathway research alternatives, see our Orforglipron (LY3502970) page. For peptide-based weight management compounds, visit our sister site Peptide-Direct →
Retatrutide's tri-agonist mechanism acts on three distinct metabolic receptors simultaneously. GLP-1 receptor agonism reduces appetite and slows gastric emptying. GIP receptor agonism enhances insulin secretion and may improve the tolerability profile of GLP-1 agonism. Glucagon receptor agonism increases hepatic glucose output and, importantly, increases energy expenditure — a mechanism not present in single or dual GLP-1 agonists.This combined receptor activity is hypothesised to produce additive or synergistic effects on weight reduction and metabolic regulation. Phase II data has reported mean weight reductions of approximately 24% or greater at higher doses over 48 weeks — among the highest figures reported for any agent in this class to date. Research areas include obesity pharmacotherapy, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and cardiometabolic risk factor reduction.
Research comparison
GLP-1 pathway agents
| Retatrutide | GLP-1 + GIP + Glucagon (triple) |
| Orforglipron | GLP-1 agonist (small molecule) |
| Tirzepatide | GLP-1 + GIP dual agonist (peptide) |
| Semaglutide | GLP-1 agonist (peptide) |
ⓘ For research reference only. Data is not directly comparable across studies or compounds.
Quality & documentation
Every batch documented
- GMP-certified manufacturing
- ISO quality management system
- HACCP-compliant production controls
- Independent third-party testing — HPLC, MS, ICP-MS
- Full analytical report (COA, HPLC, MS data) per batch
- Batch and lot traceability records
- Research Use Only labelling and export documentation included
- Temperature-controlled shipping available on request
Who orders wholesale Retatrutide
B2B buyers we supply
Contract Research Organisations
Obesity and metabolic disease research programmes.
University research groups
Triple receptor agonist pharmacology studies.
Pharmaceutical R&D teams
Comparator and reference compound supply.
Clinics & wellness businesses
GLP-1 pathway research programmes.
Qualified B2B distributors
Specialist research peptide distribution.
Shipping & delivery
Worldwide dispatch with cold chain
| EU (DE, NL, FR) | 2–4 business days |
| UK & USA | 3–6 business days |
| Canada | 4–8 business days |
| Australia | 7–12 business days |
Request a wholesale Retatrutide quote
Provide your organisation details, required quantity and shipping destination for a tailored quotation. We reply within 24 hours with a full analytical report on request.
Frequently asked questions
What is Retatrutide (LY3437943)?
Retatrutide is an investigational triple agonist peptide by Eli Lilly targeting GLP-1, GIP and glucagon receptors simultaneously. It is currently in Phase II/III development for obesity and metabolic disease, and is available for research use only.
What is the CAS number for Retatrutide?
The CAS number for Retatrutide is 2270038-40-3.
What formats is wholesale Retatrutide available in?
Lyophilised powder in sterile vials (MOQ 1g, bulk from 10g) and predosed research pens. Custom batch sizes are available on request.
What are predosed Retatrutide pens?
Prefilled research delivery devices with a dial-a-dose mechanism. They eliminate the need for manual reconstitution and syringe preparation, reducing handling steps and contamination risk in research settings.
How does Retatrutide differ from semaglutide or tirzepatide?
Retatrutide adds glucagon receptor agonism to the GLP-1 and GIP activity seen in tirzepatide. This third mechanism increases energy expenditure — not just appetite suppression — which is associated with the notably high weight reduction figures seen in Phase II data.
Do you provide COAs for wholesale Retatrutide?
Yes. Full analytical reports including COA, HPLC and MS data are included with every batch.
Retatrutide is an investigational research compound. It is not approved by any regulatory authority for human consumption, medical treatment or clinical application. All purchases are restricted to qualified institutional or professional B2B buyers. Buyers are responsible for ensuring compliance with applicable regulations in their jurisdiction.